Cymabay can’t buck the Nash disappointment trend
As placebo outperforms Cymabay’s seladelpar attention turns to the pivotal trial of Genfit’s elafibranor.
US shutdown dampens first-quarter flotations
Biopharma IPOs dipped in the opening months of 2019, but numbers look fairly healthy despite January's US government closure.
Upcoming events – a legal verdict for Enbrel and a clinical one for Cymabay
Amgen awaits a make-or-break US verdict on its best-selling drug, while Cymabay looks for evidence that it could become a Nash contender.
EASL 2019 preview – Viking and Spring Bank abstracts pique early interest
High-profile presentations from the likes of Intercept and Alnylam remain under wraps before Europe’s biggest liver disease conference next month, but the early abstract…
Ionis's third shot at the Nash target goes astray
After two other liver disease projects fade into the background Ionis delays the antisense asset AKCEA-ANGPTL3-LRx by a year.
Inventiva’s fibrosis flop hits Nash hopes
A stumble for Inventiva’s lanifibranor in a rare fibrotic disease could bode ill for its prospects in Nash, and for those of other PPAR agonists.
Intercept's Nash hopes rest on Ocaliva's borderline hit
Intercept’s Regenerate trial in Nash, one of the hottest clinical readouts of 2019, is technically a success, but toxicity casts a long shadow.
Gilead’s first big Nash bash ends in the trash
The failure of the Stellar-4 study of selonsertib is a big blow for Gilead, but has not dented enthusiasm for other Nash players.
Albireo comes up to IBAT in Nash
Albireo is taking aim at yet another Nash target, but Shire and Glaxosmithkline have already ditched projects with similar mechanisms.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.